Home > Publications database > International cooperation to fight cancer's late-stage presentation in low- and middle-income countries. > print

001     286275
005     20240229155124.0
024 7 _ |a 10.1007/s10585-022-10196-1
|2 doi
024 7 _ |a pmid:36646888
|2 pmid
024 7 _ |a pmc:PMC9898318
|2 pmc
024 7 _ |a 0262-0898
|2 ISSN
024 7 _ |a 1573-7276
|2 ISSN
037 _ _ |a DKFZ-2023-02762
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Henke, Oliver
|0 0000-0002-9838-9805
|b 0
245 _ _ |a International cooperation to fight cancer's late-stage presentation in low- and middle-income countries.
260 _ _ |a Dordrecht
|c 2023
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1703158942_2115
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:F210#
520 _ _ |a Cancer is becoming a massive public health burden in low- and middle-income countries (LMIC). 70% of all cancer deaths globally are attributed to LMIC while the incidence proportion is below 60%. The main reason for the higher mortality rate is 'late-stage presentation' of patients with stage III or IV diseases when being diagnosed. Main reasons for this are limited (financial) resources, poor knowledge of health service provider about cancer, misbelieves and fear among patients as well as low health literacy rate. During the 1st International Conference on Hospital Partnerships, conducted by the German Agency for International Cooperation (GIZ), cancer specialists from seven LMIC and Germany discussed opportunities, challenges and solutions of the development of cancer services. Two days of in-depths discussion identified five topics to be playing a key role in the effort to reduce the cancer burden in LMIC: Health Policy & Financing, Barriers to Access, Capacity Building, Cancer Registries and Adapted Treatment Guidelines. By using mind-mapping technique, stakeholders, core topics, main and important topics were visualized and interconnections displayed. Many topics can be addressed through international cooperations but political willingness and commitment in the respective countries plays the crucial role. An essential contribution will be to assist policy makers in formulating and endorsing affordable and effective health policies. Another lesson learned from this workshop is the similarity of challenges among the participating representatives from different LMIC. The authors of this letter emphasize on the importance of building international long-term cooperations to advance oncology care on a global scale.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cancer
|2 Other
650 _ 7 |a Cooperation
|2 Other
650 _ 7 |a Global oncology
|2 Other
650 _ 7 |a LMIC
|2 Other
650 _ 7 |a Metastasis
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Developing Countries
|2 MeSH
650 _ 2 |a International Cooperation
|2 MeSH
650 _ 2 |a Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Neoplasms: therapy
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
700 1 _ |a Qader, Abdul Qadir
|b 1
700 1 _ |a Malle, Goodluck Lincoln
|b 2
700 1 _ |a Kuiate, Jules Roger
|b 3
700 1 _ |a Hennig, Lisa
|b 4
700 1 _ |a Demeke, Tamiru
|b 5
700 1 _ |a Stroetmann, Clara
|b 6
700 1 _ |a Henke, Antje Anneliese
|b 7
700 1 _ |a Alaric, Tamuedjoun Talom
|b 8
700 1 _ |a Rushanyan, Marine
|b 9
700 1 _ |a Enssle, Cornell
|b 10
700 1 _ |a Bussmann, Hermann
|0 P:(DE-He78)c2b16a9737b89d371c1e6bc099412977
|b 11
|e Last author
|u dkfz
773 _ _ |a 10.1007/s10585-022-10196-1
|g Vol. 40, no. 1, p. 1 - 3
|0 PERI:(DE-600)1496876-9
|n 1
|p 1 - 3
|t Clinical & experimental metastasis
|v 40
|y 2023
|x 0262-0898
909 C O |o oai:inrepo02.dkfz.de:286275
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)c2b16a9737b89d371c1e6bc099412977
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN EXP METASTAS : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-21
920 2 _ |0 I:(DE-He78)F210-20160331
|k F210
|l KKE Angewandte Tumorbiologie
|x 0
920 1 _ |0 I:(DE-He78)F210-20160331
|k F210
|l KKE Angewandte Tumorbiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F210-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21